BTK and B-cell chronic lymphocytic leukemia: Preclinical studies revealed that nemtabrutinib inhibited kinases upstream of the BTK signaling pathway, inducing cytotoxicity in CLL cells regardless of the presence of C481S or PLCγ2 mutations.